| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥74.0B | ¥79.3B | -6.7% |
| Operating Income | ¥-1.4B | ¥-1.7B | +19.5% |
| Ordinary Income | ¥35.0B | ¥0.1B | +674.8% |
| Net Income | ¥69.0B | ¥170.7B | -59.6% |
| ROE | 15.3% | 35.9% | - |
FY2026 Q3 results: Revenue 74.0B yen (YoY -6.7%), Operating Loss 1.4B yen (improved from prior loss of 1.7B yen), Ordinary Income 35.0B yen (YoY +674.8%), Net Income 69.0B yen (YoY -59.6%). The company continues to face core business challenges with revenue contraction and operating losses, offset by extraordinary gains from equity method income of 35.0B yen primarily related to Cellebrite holdings. The stark divergence between operating loss of 1.4B yen and net income of 69.0B yen reflects the company's heavy reliance on investment-related gains rather than operational performance. Gross margin of 26.7% and SG&A ratio of 28.5% result in negative operating margin of 1.8%, indicating structural profitability challenges in the core business. Despite reported ROE of 15.3%, this metric is inflated by non-recurring investment gains and does not reflect sustainable operational earnings power.
Revenue declined 6.7% YoY to 74.0B yen, driven by contractions across major segments. Entertainment-Related segment revenue decreased 5.6% to 42.3B yen, Global Data Intelligence segment rose marginally to 8.8B yen, and IT-Related segment fell 10.9% to 23.1B yen. The newly established Wellness segment contributed no revenue but posted an operating loss of 0.2B yen, reflecting upfront investment costs. From a profit perspective, the 1.4B yen operating loss represents a 19.5% improvement from the prior period's 1.7B yen loss, primarily due to cost management rather than revenue growth. However, the business model fundamentally struggles with negative operating leverage, as the gross profit of 19.7B yen fails to cover SG&A expenses of 21.1B yen. The dramatic shift to 35.0B yen ordinary income stems entirely from equity method investment income of 35.0B yen, specifically Cellebrite-related gains as noted in segment disclosures. Net income of 69.0B yen benefited from 34.7B yen in extraordinary income, leading to an effective tax rate of only 1.0% on pre-tax profit of 69.7B yen. The 36.4B yen gap between operating loss and ordinary income represents non-operating items that are inherently volatile and non-recurring. This creates a revenue down/profit up pattern, but the profit increase is entirely attributable to investment portfolio gains rather than operational improvements, warranting significant caution regarding earnings sustainability.
Entertainment-Related segment remains the core business, generating 42.3B yen revenue (57.1% of total) with operating income of 4.5B yen and margin of 10.7%. Global Data Intelligence segment contributed 8.8B yen revenue (11.9% share) with operating income of 0.8B yen and margin of 9.6%. IT-Related segment posted 23.1B yen revenue (31.2% share) with operating income of 2.0B yen and margin of 8.7%. The newly established Wellness segment recorded an operating loss of 0.2B yen with no revenue contribution, indicating early-stage investment phase. Corporate unallocated costs totaled 8.5B yen, which when deducted from segment profits of 7.2B yen, results in the consolidated operating loss of 1.4B yen. Margin dispersion across segments is relatively narrow (8.7% to 10.7%), with Entertainment-Related maintaining the strongest profitability. The segment asset increase of 17.7B yen in Global Data Intelligence due to Cellebrite equity gain recognition highlights the portfolio's investment nature rather than operational asset base expansion.
[Profitability] ROE of 15.3% appears elevated but is entirely driven by non-recurring investment gains rather than operational performance, with the company's operating margin at negative 1.8% (operating loss of 1.4B yen on revenue of 74.0B yen). Net profit margin of 93.2% is artificially inflated by equity method income and extraordinary gains totaling over 69B yen, masking the fundamental unprofitability of core operations. ROA of 13.4% similarly reflects investment gains rather than asset productivity. [Efficiency] Asset turnover of 0.144 is substantially below the manufacturing industry median of 0.56, indicating poor asset utilization. Receivables turnover of 79 days and inventory turnover of 245 days both exceed industry norms significantly (industry medians of 85 days and 112 days respectively), pointing to working capital management inefficiencies. [Financial Health] Equity ratio of 87.3% substantially exceeds the industry median of 63.8%, reflecting conservative capital structure, though this partially results from accumulated investment gains in equity. Current ratio of 149.6% appears adequate but cash coverage of short-term liabilities at 0.83x indicates liquidity tightness, as cash and deposits of 24.3B yen fall short of short-term borrowings of 29.2B yen. Interest-bearing debt totals 31.0B yen with debt-to-equity ratio of 0.065, indicating low leverage, though negative interest coverage of -5.86x reflects the operating loss relative to interest expense of 0.2B yen.
Cash and deposits declined from 24.3B yen to 24.3B yen (minimal change), while the company generated significant accounting profits of 69.0B yen, suggesting substantial cash outflows or non-cash profit recognition. The divergence between operating loss of 1.4B yen and net income of 69.0B yen indicates that equity method gains of 35.0B yen and extraordinary gains of 34.7B yen are largely non-cash items or not immediately convertible to operating cash. Working capital shows strain with receivables at 16.0B yen and inventories totaling 36.4B yen (including finished goods 4.5B yen, raw materials 27.6B yen, and work in process 4.3B yen), representing significant capital tied up relative to quarterly revenue of 74.0B yen. Trade payables of 9.8B yen provide limited financing relief. Short-term borrowings increased from 22.9B yen to 29.2B yen, representing a 27.3% rise that likely reflects working capital financing needs rather than growth investment. The company's ability to sustain operations appears dependent on refinancing short-term debt and monetizing investment portfolio gains, as the core business generates operating losses. Contract liabilities of 15.7B yen provide some forward revenue visibility but also represent deferred performance obligations requiring cash investment to fulfill.
Ordinary income of 35.0B yen versus operating loss of 1.4B yen reveals non-operating net contribution of approximately 36.4B yen, comprising primarily equity method gains of 35.0B yen. Non-operating income represents 50.2% of total ordinary income, consisting almost entirely of investment portfolio fluctuations rather than recurring business operations. Additionally, extraordinary income of 34.7B yen includes gains on changes in equity interest and other one-time items, with impairment losses of 0.3B yen partially offsetting these gains. The cumulative non-operating and extraordinary items of over 71B yen dwarf the operating loss, creating significant earnings quality concerns. The effective tax rate of 1.0% (tax expense of 0.7B yen on pre-tax profit of 69.7B yen) is abnormally low, potentially reflecting deferred tax asset recognition or tax benefits on capital gains. Operating cash flow data is unavailable for quarterly periods, preventing verification of cash conversion. The substantial share of other comprehensive loss of 16.4B yen from equity method investees reduces comprehensive income to 54.2B yen from net income of 69.0B yen, indicating mark-to-market volatility in the investment portfolio. Overall earnings quality is poor, with the core business generating losses while profits derive from volatile, non-recurring investment portfolio movements.
Full-year guidance projects revenue of 103.0B yen (YoY -5.0%), operating loss of 2.1B yen, ordinary income of 55.0B yen (YoY +674.8%), and net income of 88.0B yen. Q3 cumulative progress represents 71.8% of revenue target, -64.8% of operating loss forecast (indicating operating performance slightly ahead of lowered expectations), 63.6% of ordinary income forecast, and 78.4% of net income target. The revenue progress rate of 71.8% at Q3 is below the standard 75% benchmark, suggesting potential full-year revenue shortfall risk or backend weighting. However, ordinary income and net income progress exceed 60%, indicating the company expects further investment portfolio gains or one-time items in Q4 to reach the 88.0B yen net income target. The forecast was revised during the quarter, reflecting updated assumptions on investment gains and core business trajectory. The company notes in forecast assumptions that actual results may differ materially due to various factors, and management acknowledges uncertainty regarding the realization of investment-related gains. Contract liabilities of 15.7B yen represent 15.2% of forecasted annual revenue, providing modest forward visibility, though this backlog-to-revenue ratio of 0.15x is relatively low for manufacturing operations with extended production cycles.
Annual dividend per share is planned at 100 yen (interim 50 yen plus year-end 50 yen), maintaining the prior year's level. Based on net income of 69.0B yen for nine months and average shares outstanding of 22.0M shares, the payout ratio calculates to approximately 31.9% on an annualized basis using full-year forecasted net income of 88.0B yen. The dividend appears sustainable from an earnings coverage perspective; however, the source of earnings is predominantly non-recurring investment gains rather than operating cash flow. Year-end dividend remains undetermined according to company disclosure, introducing uncertainty. Treasury stock increased substantially from 3.6B yen to 10.8B yen (200.4% increase), indicating share buyback activity of approximately 7.2B yen during the period. Calculating total shareholder returns, dividends of approximately 2.2B yen (100 yen times 22M shares) plus buybacks of 7.2B yen sum to 9.4B yen, representing a total return ratio of approximately 13.6% relative to net income of 69.0B yen, or 10.7% against forecasted full-year net income of 88.0B yen. This aggressive capital return policy is notable given the company operates at an operating loss, suggesting management prioritizes returning investment gains to shareholders rather than reinvesting in the struggling core business.
Core business profitability deterioration represents the primary risk, with operating losses of 1.4B yen indicating fundamental structural challenges in achieving positive margins. Revenue declined 6.7% YoY with gross margin of 26.7% insufficient to cover SG&A expenses of 28.5%, and absent dramatic cost restructuring or revenue recovery, the company faces continued operational cash burn. The Wellness segment's startup losses add near-term pressure without offsetting revenue contributions.
Dependence on volatile investment portfolio gains creates severe earnings unpredictability, as 99% of current profits derive from equity method income and extraordinary items totaling over 69B yen. The Cellebrite equity position and other holdings are subject to market volatility, investee company performance, and potential impairment. Any adverse movement in these investments would eliminate profitability entirely, given the operating loss foundation. The company provides no visibility into the sustainability or recurrence of these gains.
Liquidity and refinancing risk emerges from high short-term debt concentration, with 94.1% of liabilities being current and short-term borrowings of 29.2B yen exceeding cash reserves of 24.3B yen. Working capital efficiency deterioration (receivables turnover 79 days, inventory turnover 245 days) constrains operating cash generation. Interest coverage is negative at -5.86x, and any tightening of credit conditions or inability to roll over short-term facilities could precipitate a liquidity crisis. The company's 27.3% increase in short-term borrowings despite high reported profits suggests ongoing operating cash consumption.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating margin of -1.8% significantly underperforms the manufacturing industry median of 8.9%, with the company falling in the bottom decile. Net profit margin of 93.2% vastly exceeds the industry median of 6.5%, but this outlier performance reflects non-recurring investment gains rather than operational strength. ROE of 15.3% appears to exceed the industry median of 5.8%; however, adjusting for the extraordinary nature of earnings reveals sustainable ROE is likely negative given operating losses.
Financial Health: Equity ratio of 87.3% substantially exceeds the industry median of 63.8%, positioning the company in the top quartile for balance sheet strength. Current ratio of 149.6% falls below the industry median of 287%, indicating relatively weaker liquidity despite the high equity base. Financial leverage of 1.15x is substantially lower than the industry median of 1.53x, reflecting conservative debt utilization.
Efficiency: Asset turnover of 0.144 severely lags the industry median of 0.56, placing the company in the bottom quartile and suggesting inefficient deployment of the large investment portfolio. Operating working capital turnover of 324 days (combining receivables 79 days, inventory 245 days, less payables) far exceeds the industry median of 112 days, indicating substantial working capital inefficiency. Receivables and inventory management both require significant improvement to approach peer levels.
Growth: Revenue decline of 6.7% YoY contrasts unfavorably with the industry median growth of 2.8%, placing the company in the bottom quartile for top-line performance. EPS growth YoY of -59.1% (from 767 yen to 313.34 yen) substantially underperforms the industry median of 9%, though this comparison is distorted by the prior year's even larger extraordinary gains.
(Industry: Manufacturing sector, N=105 companies, Comparison: FY2025-Q3 data, Source: Proprietary analysis)
The company's financial profile reflects a manufacturing business in operational distress being temporarily masked by substantial investment portfolio gains. Operating losses of 1.4B yen and revenue contraction of 6.7% indicate core business deterioration, with gross margins of 26.7% insufficient to cover SG&A expenses of 28.5%. The negative operating margin of 1.8% and bottom-quartile asset turnover of 0.144x (versus industry median 0.56x) demonstrate fundamental operational inefficiency. Without restructuring to achieve positive operating leverage, the core business trajectory points toward continued value destruction. The Entertainment-Related segment, while contributing 57% of revenue, operates at only 10.7% margin, and the new Wellness segment adds losses without revenue contribution, suggesting diversification efforts have yet to yield returns.
The dramatic divergence between 1.4B yen operating loss and 69.0B yen net income highlights extreme dependence on non-recurring investment gains, specifically 35.0B yen equity method income from Cellebrite and 34.7B yen extraordinary income. These items represent 99% of reported profits and are inherently volatile and non-repeatable. The company's ability to sustain dividends of 100 yen per share and aggressive share buybacks totaling 7.2B yen relies entirely on monetizing investment portfolio gains rather than generating operating cash flow. This creates significant earnings sustainability risk, as any adverse investment portfolio performance would result in substantial losses given the negative operating base. The full-year forecast of 88.0B yen net income similarly assumes continued investment gains, providing no visibility into operational recovery.
Liquidity concerns warrant close monitoring, with cash coverage of short-term liabilities at only 0.83x and 94.1% short-term debt concentration creating refinancing risk. Working capital inefficiency, evidenced by 245-day inventory turnover and 79-day receivables collection (both substantially worse than industry medians), constrains operating cash generation. The 27.3% increase in short-term borrowings to 29.2B yen despite high reported profits suggests the company consumes cash operationally. Combined with negative interest coverage of -5.86x, any tightening of credit availability or rise in borrowing costs could pressure the balance sheet. The high equity ratio of 87.3% and contract liabilities of 15.7B yen provide buffers, but the fundamental challenge remains achieving positive operating cash flow to reduce reliance on external financing and investment portfolio liquidations.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.